Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant

Leukemia. 2021 Nov;35(11):3278-3281. doi: 10.1038/s41375-021-01229-x. Epub 2021 Mar 26.
No abstract available

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Combined Modality Therapy
  • Drug Resistance, Neoplasm*
  • Female
  • Follow-Up Studies
  • Glycine / analogs & derivatives*
  • Glycine / therapeutic use
  • Hematopoietic Stem Cell Transplantation / mortality*
  • Humans
  • Isocitrate Dehydrogenase / genetics*
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / mortality*
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Myeloid, Acute / therapy
  • Male
  • Middle Aged
  • Mutation*
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / mortality*
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy
  • Prognosis
  • Pyridines / therapeutic use*
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Pyridines
  • Isocitrate Dehydrogenase
  • IDH1 protein, human
  • ivosidenib
  • Glycine